{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040499","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.301404+00:00","generated_at":"2026-06-08T05:57:40.876378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enveric Biosciences reports Q3 2023 net loss of $2.82M; cash $4.27M; advances psychedelic pipeline","bullets":["Net loss of $2.82M ($1.30 per share) vs $2.60M ($1.46 per share) in Q3 2022.","Cash and cash equivalents of $4.27M as of Sept 30, 2023.","Granted two US patents for EVM301 Series and EB-373; filed six non-US applications.","Completed manufacturing of EB-373; preclinical data show oral bioavailability and safety.","AI drug discovery engine Psybrary surpassed 1,000 compounds analyzed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040499","json":"https://secwatch.observer/filing/0001493152-23-040499.json","markdown":"https://secwatch.observer/filing/0001493152-23-040499.md","text":"https://secwatch.observer/filing/0001493152-23-040499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/0001493152-23-040499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:57:40.876378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fdf1e0e676da68d21bf4c0b8bb4c15a40a8d3821","claim":"Enveric Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/0001493152-23-040499-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}